Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). (February 2017)

• Record Type: Journal Article
• Authors: Tiseo, Marcello; Damato, Angela; Longo, Lucia; Barbieri, Fausto; Bertolini, Federica; Stefani, Alessandro; Migaldi, Mario; Gnetti, Letizia; Camisa, Roberta; Bordi, Paola; Buti, Sebastiano; Rossi, Giulio
• Is Part Of: Lung cancer. Volume 104(2017)
• Page Start: 24
• Page End: 30
• Publication Date: 2017-02
• Subjects: Thymoma -- Thymic carcinoma -- Gene mutations -- c-KIT -- PD-L1; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2016.12.005
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Thymic epithelial tumors (TETs) are rare neoplasms with different prognosis. The identification of new targets an emerging need in TET management. A panel of 7 druggable genes and ALK and PD-L1 expression was evaluated. Thymic carcinoma can harbor c-KIT mutations and elevated PD-L1 expression. c-KIT mutations and PD-L1 could represent targets of potential therapeutic use. Abstract: Introduction: Thymic epithelial tumors (TETs) are rare neoplasms with different prognosis lacking consistent molecular alterations possibly leading to targeted therapy. We collected a consecutive series of TETs aimed at investigating the mutational status of druggable genes ( EGFR, c-KIT, KRAS, BRAF, PDGFR-alpha and − beta, HER2 and c-MET ) and the expression of ALK and PD-L1. Patients and methods: One hundred twelve consecutive cases of TETs and relative clinico-pathologic features were collected. Immunohistochemical expression of ALK (clone D5F3) and PD-L1 (clone E1L3N), molecular analysis of EGFR (exons 18–21), c-KIT (exons 9, 11, 13, 14, 17), KRAS (exon 2), BRAF (exon 15), PDGFR-alpha (exon 12) and -beta (exons 12, 14, 18), HER-2 (exons 19 and 20) and c-MET (exons 14, 17, 18, 19) mutations were performed. Immuno-molecular results were then statistically matched with clinico-pathologic characteristics. Results: Patients were male in 54% of cases, with a median age of 61 years (range 19–83) and affected mainly by thymoma (78%) in stage II (45%). At molecular analysis, there were 4 c-KIT mutations (occurring in exon 11 V559A, L576P, Y553N and exon 17 D820E) in thymic carcinomas (type C), but not in other tumor types (p = 0.003). No mutations were detected in other genes and none case was ALK positive. Twenty-nine (26%) cases were PD-L1 positive (65% of thymic carcinomas and 18% of thymomas). High PD-L1 expression was statistically associated with WHO classification stage type C ( p < 0.001) and Masaoka stage III–IV disease ( p = 0.007). In univariate analysis, WHO classification type C, advanced Masaoka stage and absence of myasthenia, but not PD-L1 expressions were correlated with worse survival; at multivariate analysis, only WHO type C confirmed its negative prognostic role. Conclusion: A subset of TETs as thymic carcinomas can harbor c-KIT mutations and elevated PD-L1 expression that could represent targets of potential therapeutic use.